ストックスクリーナーアプリを入手
8.43
1.93%
0.16
アフターアワーズ：
8.36
-0.07
-0.83%
前日終値:
$8.27
開ける：
$8.21
24時間の取引高:
6.07M
Relative Volume:
0.71
時価総額：
$2.89B
収益：
-
当期純損益:
$-75.80M
株価収益率:
-24.09
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
-1.40%
1か月 パフォーマンス:
+70.99%
6か月 パフォーマンス:
+365.75%
1年 パフォーマンス:
+220.53%
1日の値動き範囲:
$8.00
$8.55
1週間の範囲:
$7.80
$8.9524
52週間の値動き範囲:
$1.54
$8.9524
Nuvation Bio Inc Stock (NUVB) Company Profile
名前
Nuvation Bio Inc
セクター
電話
(415) 754-3517
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
8.43 | 2.84B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-19 | 開始されました | B. Riley Securities | Buy |
| 2025-09-30 | 開始されました | Jefferies | Buy |
| 2025-04-23 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-03-27 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-26 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | 開始されました | BMO Capital Markets | Outperform |
| 2021-03-08 | 開始されました | BTIG Research | Buy |
| 2021-03-08 | 開始されました | Cowen | Outperform |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Nuvation Bio Inc (NUVB) 最新ニュース
Gap Down: How Nuvation Bio Inc stock reacts to oil prices2025 EndofYear Setup & High Conviction Buy Zone Picks - moha.gov.vn
Nuvation Bio Stock Surges Amid Price Target Boost - TipRanks
Nuvation Bio stock price target raised to $18 from $10 at H.C. Wainwright By Investing.com - Investing.com South Africa
Nuvation Bio stock price target raised to $18 from $10 at H.C. Wainwright - Investing.com Nigeria
HC Wainwright & Co. Maintains Nuvation Bio (NUVB) Buy Recommendation - Nasdaq
Nuvation Bio (NUVB): Reassessing Valuation After Safusidenib Data and Taletrectinib China Reimbursement News - Sahm
Nuvation Bio Inc. $NUVB is Omega Fund Management LLC's 4th Largest Position - MarketBeat
Nuvation Bio (NUVB) price target increased by 12.48% to 10.65 - MSN
Nuvation Bio (NYSE: NUVB) partner taletrectinib added to China's 2025 NRDL - Stock Titan
Nuvation Bio (NUVB) Price Target Increased by 12.48% to 10.65 - Nasdaq
Tema Etfs LLC Purchases Shares of 139,648 Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Nuvation Bio (NUVB) bounces back 12% on impressive clinical trial result - MSN
Why Nuvation Bio Inc. Class stock is a strong analyst pickPortfolio Update Report & Verified Momentum Stock Alerts - Newser
Cash per share of Nuvation Bio Inc. – NYSE:NUVB - TradingView
Will Nuvation Bio Inc. Warrants stock profit from AI boom2025 Risk Factors & Technical Buy Zone Confirmations - Newser
Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells 150,000 Shares of Stock - MarketBeat
Why millennials buy Nuvation Bio Inc. Warrants stockJuly 2025 Summary & Risk Managed Investment Signals - Newser
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result - Insider Monkey
Nuvation Bio (NYSE:NUVB) Stock Price Up 8.9%Still a Buy? - MarketBeat
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio’s chief medical officer sells $1.17 million in stock By Investing.com - Investing.com South Africa
Nuvation Bio (NYSE:NUVB) Hits New 1-Year HighHere's What Happened - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will Nuvation Bio Inc. Class stock profit from AI boomJuly 2025 Selloffs & Trade Opportunity Analysis Reports - Newser
10 Stocks Stealing Market Spotlight - Insider Monkey
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology - Investing News Network
Nuvation Bio’s Surge: Buy or Observe? - StocksToTrade
ETFs Investing in Nuvation Bio Inc. Stocks - TradingView
Nuvation Bio’s chief medical officer sells $1.17 million in stock - Investing.com
Nuvation Bio Insider Sold Shares Worth $1,173,255, According to a Recent SEC Filing - marketscreener.com
Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise - Stock Titan
Nuvation Bio stock hits 52-week high at $8.24 - Investing.com
Nuvation Bio stock hits 52-week high at $8.24 By Investing.com - Investing.com Nigeria
NUVB: Iptrozi and Safusidenib show strong clinical and commercial momentum, driving major growth potential - TradingView
NUVB: Iptrozi and Safusidenib drive strong growth, with robust financials and pipeline innovation - TradingView
Nuvation Bio: Phase 2 study results in IDH1-mutant gliomas published - Traders Union
Will Nuvation Bio Inc. Warrants stock benefit from sector leadershipWeekly Loss Report & Real-Time Volume Analysis - Newser
Geode Capital Management LLC Acquires 864,194 Shares of Nuvation Bio Inc. $NUVB - MarketBeat
Will Nuvation Bio Inc. Class stock outperform benchmarks2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Can Nuvation Bio Inc. Class stock surprise markets with earningsPortfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - Newser
Is Nuvation Bio Inc. stock a safe buy before earningsTreasury Yields & AI Enhanced Market Trend Forecasts - Newser
Officer Liu Files To Sell 150,000 Of Nuvation Bio Inc [NUVB] - TradingView
H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 target - Investing.com Canada
HC Wainwright & Co. Reiterates Nuvation Bio (NUVB) Buy Recommendation - Nasdaq
What is Wedbush's Estimate for Nuvation Bio FY2027 Earnings? - MarketBeat
Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
Nuvation Bio’s Strategic Dilemma: Navigating Taletrectinib’s Global Commercialization Risks - MSN
Nuvation Bio: A Strong Company Now Fairly Priced - Seeking Alpha
Nuvation Bio Inc (NUVB) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):